Update-1 Gene Editing stocks are hit hard by a STAT Report that edited cells may cause cancer. Here is a later summary from STAT. As of 2:45 PDT trading; CRSP down 12% at $60, EDIT down 7.8% at $36.14. NTLA down 9.9% at $24.5. The report was published in Nature Medicine.
After the close biotech stocks were mixed with some notable winners: BPMC, ECYT, IONS, SGEN.
Mid-Cap Biotechs: Performance Post ASCO
We will update our biotech mid-cap performance list on Tuesday but here are the momentum leaders near 52 week highs after ASCO news and updates.We will also update our mid-cap list at the six month mark.
52 Week leaders
AGIO, ARRY, CRSP, FMI, FOLD, GWPH, LGND, LOXO, NBIX, SGEN, SRPT
52 Week laggards
ACAD, ANAB, CLVS, EXEL, INCY, IONS, TSRO